Alaskan Malamute Polyneuropathy: Testing and Heredity Guide
Alaskan Malamute Polyneuropathy (AMPN) is a hereditary neuromuscular disorder affecting the Alaskan malamute breed. It causes progressive muscle atrophy and abnormal hind leg movement, leading to a distinctive gait. Signs generally appear in younger dogs between 3 months and 2 years of age, often first noticeable when walking up or down stairs or inclines.
As a genetic condition, AMPN is passed down through breed lines by parents and ancestors. It cannot be caught from other dogs casually. Pre-breeding DNA testing is vital to determine if an Alaskan malamute is clear, a carrier, or affected, enabling informed breeding decisions to reduce the risk of affected puppies.
Understanding Alaskan Malamute Polyneuropathy
AMPN is also called idiopathic polyneuropathy. It involves degeneration of the peripheral nerves, resulting in muscle weakness and loss of nerve control to limbs. Clinical signs include ataxia, unusual walking on toes, and regular stumbling or falling.
Typically, symptoms emerge before the dog reaches two years old, worsening progressively and affecting quality of life.
Which Dogs Are at Risk?
This condition exclusively affects purebred Alaskan malamutes, though crossbreeds with Alaskan malamute ancestry may also inherit the gene mutation. Interestingly, a similar polyneuropathy occurs in Greyhounds, but this is due to a different genetic mutation and is tested separately.
Genetic Inheritance of AMPN
AMPN follows an autosomal recessive inheritance pattern. A dog must inherit two copies of the mutated NDRG1 gene, one from each parent, to be affected.
Dogs are classified into three genetic statuses after testing:
- Clear (N/N): No copies of the mutation; will not develop AMPN and cannot pass it on.
- Carrier (N/Mut): One copy of the mutation; healthy but can pass the gene to offspring.
- Affected (Mut/Mut): Two copies; will develop AMPN.
Key breeding combinations and outcomes:
- Clear x Clear: All puppies clear.
- Clear x Carrier: 50% clear, 50% carrier.
- Carrier x Carrier: 25% clear, 50% carrier, 25% affected.
- Carrier x Affected: 50% carrier, 50% affected.
- Affected x Affected: All puppies affected.
Breeding two carriers without testing risks producing affected puppies, making DNA testing essential.
How to Test Your Alaskan Malamute
Testing is essential for responsible breeding. The test requires either a DNA sample from a cheek swab or an EDTA blood sample collected by a vet. These samples are sent to accredited laboratories for analysis, resulting in a genetic status classification.
Testing is available for all Alaskan malamutes, including those without pedigree documents. This ensures even non-registered dogs can contribute to reducing AMPN within the breed.
Responsible Breeding and Ownership
Responsible breeders use DNA test results to guide their breeding decisions, aiming to produce clear or carrier puppies but never affected ones. Breeding a carrier with a clear dog produces only clear or carrier offspring, never affected dogs, making this an acceptable approach while working to reduce the mutation in the breed.
Buyers should request AMPN test results for both parents to ensure they are purchasing from responsible breeders who prioritise the health and welfare of Alaskan malamutes.
This responsible approach ultimately supports the long-term health of the breed and ensures new generations are increasingly free of AMPN.
Related articles
Final thoughts on alaskan malamute polyneuropathy
Alaskan Malamute Polyneuropathy is a serious hereditary condition that can be managed through genetic testing and informed breeding. Responsible Alaskan malamute owners and breeders who test for and consider AMPN status are helping to secure a healthier future for the breed.
If looking to find an Alaskan malamute puppy, always check if the breeder has carried out AMPN testing on both parents to ensure you are supporting responsible breeding practices.
